Why Is ERASCA INC (ERAS) Stock Down Today?

Erasca stock fell 7.40% to $13.77 on October 16, 2026. The primary driver was a leadership realignment announced to better support the development of its RAS oncology programs.

What Happened

Erasca, Inc. announced a leadership realignment on October 15, 2026, aimed at supporting the development and potential commercialization of its RAS oncology programs. The company filed a Form 8-K with the SEC on October 16, disclosing the departure of directors or certain officers and the appointment of new officers. This structural change coincided with a broader review of the company’s position in the KRAS inhibitor market, where it holds Fast Track status for ERAS-0015 in metastatic pancreatic adenocarcinoma.

What The Data Shows

The stock opened at $14.81 and hit a session high of $14.91 at 8:10 AM ET before sliding to a low of $13.73 at 9:55 AM ET. Trading volume stood at 0.2 million shares, which is 0.1 times the three-month daily average. Erasca has a market capitalization of $5.1 billion and remains unprofitable with a trailing twelve-month EPS of -0.97. The stock has a beta of 0.62 and a 52-week range of $2.10 to $24.28. Over the last eight sessions, the stock had moved up 3.0% from $14.30 to $14.73. On October 16, the stock printed 13 fresh 52-week lows. Recent analyst activity includes Bank of America Securities maintaining a Neutral rating with a $20 price target, Guggenheim maintaining a Buy rating with a $21 target, and HC Wainwright & Co. maintaining a Buy rating with a $22 target.

What To Watch

Investors will monitor the impact of the new leadership structure on the progress of ERAS-0015, which is targeted for trials in 2027. The company’s ability to advance its KRAS inhibitor program while managing its unprofitable status will be key factors in the coming months.